SC Pharmaceuticals Inc (SCPH) Stock Price, Quote & News

Company Profile

scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresi...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 517 0730

Website: www.scpharmaceuticals.com

Address:

25 Mall Road, Suite 203, Burlington, United States

ZacksResearch Sep. 10 at 1:47 PM

$MNKD up 60% in a month — can the momentum keep running? 🚀 🔥 Pipeline is firing: Afrezza sBLA for pediatrics under FDA review, MNKD-101 Phase 3 ahead of schedule, MNKD-201 set for Phase 2 by year-end. 🤝 Expanded $UTHR collab adds another pulmonary hypertension therapy + $5M upfront + milestones + royalties. 💰 $360M acquisition of $SCPH brings FUROSCIX with a $10B U.S. market opportunity in CHF & CKD. Latest MNKD news here 👉 https://www.zacks.com/stock/quote/MNKD?q=MNKD&cid=sm-stocktwits-0-quote_overview-oc-11693&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_11693

0 · Reply

Fire7878 Sep. 10 at 5:55 AM

$SCPH do yall find it a bit interesting that the short position from April to June was covered ahead of the aquistion without any changes to trajectory of sales? For one 2 week period the short covering position was more than the total traded volume in that period. Senanigans!

0 · Reply

clan Sep. 6 at 4:38 PM

$MNKD 🦆🦆🦆🦆🦆🦆🦆🦆🦆🦆 A lot of ducks. $UTHR $SCPH

1 · Reply

smartkarma Sep. 5 at 4:19 PM

$SCPH | Merger and Acquisition Updates: TaskUs, scPharmaceuticals, Apiam, Plymouth, Mayne Pharma, Banxa, and DallasNews "TaskUs privatization bid at $16.50/share faces opposition; market anticipates improved offer before September 10 shareholder vote." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/merger-and-acquisition-updates-taskus-scpharmaceuticals-apiam-plymouth-mayne-pharma-banxa-and-dallasnews

0 · Reply

clan Sep. 5 at 3:01 PM

$MNKD $UTHR $SCPH $BXSL Mannkind is like a growing magnet with an attraction the is getting bigger. #PartnershipsAndMergers 💎👐

0 · Reply

clan Sep. 5 at 2:33 PM

$MNKD The stock manipulation will end and MNKD will see HUGE(r) green gains. For the good of investors of $UTHR & $SCPH who have bought into MNKD.

0 · Reply

Moneyriver Sep. 4 at 5:41 PM

$SCPH This is a horrible deal MNKD is a chop-shop not that SCPH is much better but both are fleas on the ass of real companies

0 · Reply

smartkarma Sep. 4 at 1:01 PM

$SCPH | MannKind's Acquisition of scPharmaceuticals: Strategic CVR Valuation and FDA Approval Prospects for SCP-111 "MannKind acquires scPharmaceuticals for $5.35/share plus a CVR up to $1.00; market values CVR at $0.17." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/mannkind-s-acquisition-of-scpharmaceuticals-strategic-cvr-valuation-and-fda-approval-prospects-for-scp-111

0 · Reply

NVDAMillionaire Sep. 3 at 2:50 PM

$SCPH Great piece that accurately captures SCPH's current position. So if you want to refresh your understanding of SCPH or learn about SCPH for the first time, this is essential reading. https://beyondspx.com/quote/SCPH/scph-unlocking-cardiorenal-care-s-future-through-subcutaneous-innovation#analysis

0 · Reply

clan Sep. 3 at 10:40 AM

$MNKD $SCPH $UTHR Product offerings/availabilities update coming. Be one of the cool kids. "The Fix Is In!"

1 · Reply

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

MNKD

Aug 25, 2025, 7:31 AM EDT - 16 days ago

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

Aug 14, 2025, 8:30 AM EDT - 27 days ago

scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111

Aug 8, 2025, 2:09 PM EDT - 4 weeks ago

scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 4 weeks ago

scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 4:01 PM EDT - 5 weeks ago

scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

May 22, 2025, 7:29 AM EDT - 3 months ago

scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025

May 15, 2025, 12:15 AM EDT - 4 months ago

scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:01 PM EDT - 4 months ago

scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 4:01 PM EDT - 4 months ago

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

May 1, 2025, 4:01 PM EDT - 4 months ago

scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences

Mar 19, 2025, 7:13 PM EDT - 6 months ago

scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 4:01 PM EDT - 6 months ago

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 12, 2025, 4:01 PM EDT - 6 months ago

scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

Mar 6, 2025, 4:01 PM EST - 6 months ago

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease

Feb 26, 2025, 4:01 PM EST - 6 months ago

scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences

Feb 5, 2025, 4:01 PM EST - 7 months ago

scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 10, 2025, 8:00 AM EST - 8 months ago

scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Nov 13, 2024, 7:05 PM EST - 10 months ago

scPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:01 PM EST - 10 months ago

scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 4:01 PM EST - 10 months ago

scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

Oct 15, 2024, 8:30 AM EDT - 11 months ago

scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024

Aug 15, 2024, 5:10 AM EDT - 1 year ago

scPharmaceuticals Inc. (SCPH) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:01 PM EDT - 1 year ago

scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 9:48 AM EDT - 1 year ago

scPharmaceuticals Announces Pricing of $50.0 Million Public Offering

Aug 12, 2024, 6:05 AM EDT - 1 year ago

scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors

Aug 12, 2024, 6:04 AM EDT - 1 year ago

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure

Aug 12, 2024, 6:02 AM EDT - 1 year ago

scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector

Aug 12, 2024, 6:00 AM EDT - 1 year ago

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

May 29, 2024, 4:01 PM EDT - 1 year ago

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 7:02 PM EDT - 1 year ago

scPharmaceuticals Inc. (SCPH) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:01 PM EDT - 1 year ago

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 4:05 PM EDT - 1 year ago

scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 7, 2024, 4:05 PM EDT - 1 year ago

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Apr 24, 2024, 8:00 AM EDT - 1 year ago

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

Mar 13, 2024, 7:32 PM EDT - 1 year ago

scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 4:01 PM EDT - 1 year ago

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 4:01 PM EST - 1 year ago

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

Feb 28, 2024, 4:01 PM EST - 1 year ago

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

Jan 4, 2024, 4:05 PM EST - 1 year ago

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Nov 12, 2023, 2:57 AM EST - 1 year ago

scPharmaceuticals Q3 Earnings: Cruising Toward Success

Nov 8, 2023, 9:58 PM EST - 1 year ago

scPharmaceuticals Inc (SCPH) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:01 PM EST - 1 year ago

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 1, 2023, 4:05 PM EDT - 2 years ago

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

Oct 5, 2023, 8:00 AM EDT - 2 years ago

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 27, 2023, 12:40 AM EDT - 2 years ago

scPharmaceuticals: Furoscix, Charting A Bright Future With FDA's Nod For CKD

Sep 19, 2023, 8:00 AM EDT - 2 years ago

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

ZacksResearch Sep. 10 at 1:47 PM

0 · Reply

Fire7878 Sep. 10 at 5:55 AM

0 · Reply

clan Sep. 6 at 4:38 PM

$MNKD 🦆🦆🦆🦆🦆🦆🦆🦆🦆🦆 A lot of ducks. $UTHR $SCPH

1 · Reply

smartkarma Sep. 5 at 4:19 PM

0 · Reply

clan Sep. 5 at 3:01 PM

$MNKD $UTHR $SCPH $BXSL Mannkind is like a growing magnet with an attraction the is getting bigger. #PartnershipsAndMergers 💎👐

0 · Reply

clan Sep. 5 at 2:33 PM

$MNKD The stock manipulation will end and MNKD will see HUGE(r) green gains. For the good of investors of $UTHR & $SCPH who have bought into MNKD.

0 · Reply

Moneyriver Sep. 4 at 5:41 PM

$SCPH This is a horrible deal MNKD is a chop-shop not that SCPH is much better but both are fleas on the ass of real companies

0 · Reply

smartkarma Sep. 4 at 1:01 PM

0 · Reply

NVDAMillionaire Sep. 3 at 2:50 PM

0 · Reply

clan Sep. 3 at 10:40 AM

$MNKD $SCPH $UTHR Product offerings/availabilities update coming. Be one of the cool kids. "The Fix Is In!"

1 · Reply

jerrybe5000 Sep. 2 at 9:01 PM

$SCPH Mannkind stole the company. People are starting to realize it.

0 · Reply

clan Sep. 2 at 6:31 PM

$MNKD $SCPH Here is what to expect around here/Mannkind/MNKD over the next 16 months...

0 · Reply

clan Sep. 2 at 3:02 PM

$MNKD $UTHR $SCPH Tomorrow afternoon, and then again Thursday morning. A lot to discuss. STAY TUNED! 👀 👂 Sounds like "lasagna".

0 · Reply

clan Sep. 2 at 12:03 PM

$MNKD $UTHR $SCPH Today is one of those days! Yabba Dabba DOOO!

0 · Reply

kcphaeton Aug. 30 at 1:00 AM

$MNKD if $SCPH was so valuable (price targets) according analysts how did they accept such a lowball offer? scPharmaceuticals (SCPH) analysts hold mixed to positive ratings, with a current consensus of "Hold" by some analysts, while others maintain a "Strong Buy" rating based on strong recent Furoscix sales growth and expanding market demand. However, analysts also cite concerns about missed earnings expectations and higher-than-forecast losses per share. Price targets vary, with median targets ranging from $12 to $25, indicating a significant potential upside according to some forecasts.

2 · Reply

clan Aug. 29 at 5:34 PM

Here's why $MNKD could be in the mid $60S by late 2028.... APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [B4 EOY 2028]: + $4 -- acquisition of scPharma $SCPH + $6 -- Furoscix auto injector +$10 -- pediatric Afrezza + $3 -- gestational Afrezza + $5 -- 2nd Unither DPI drug $UTHR + $7 -- Clofazimine nebulized (CIS) + $3 -- Clofazimine DPI +$12 -- Nintedanib DPI + $4 -- TYVASO for IPF + $6 -- TYVASO for PPF [Source: C.I.A.]

1 · Reply

Fire7878 Aug. 29 at 4:38 PM

moved my holding from $SCPH to $ZVRA. I thinking cleaning the books earnings resulted in great opportunity to buy a dip and the march up. Hope this one doesnt agree to a low ball BO offer, seems cash poaition stronger and already getting great market pentration.

0 · Reply

MITornado Aug. 28 at 6:30 PM

$MNKD $SCPH nobody here thinks a 1.4 billion valuation is a bit high? I’m headed to ELTP. Tell Beef 🥩 I said ✌🏻 😘

2 · Reply

uscharalph Aug. 28 at 11:52 AM

$SCPH Do you think this deal will pass the proxy vote?

2 · Reply

clan Aug. 28 at 12:43 AM

$MNKD 2026 - transformative - inflection point - from rest to grow - proper valuation. Thanks for the assist $BX $UTHR $SCPH [source: Clan Investment Advisor]

0 · Reply

uscharalph Aug. 27 at 7:58 PM

$SCPH We haven't seen a mass exodus from this stock. Wondering what the institutions are doing? Will they vote for the deal?

2 · Reply

JackFlaps Aug. 27 at 1:41 PM

$SCPH law firms already investigating whether Tucker and his merry band of morons (BOD) misled and defrauded shareholders accepting an unacceptable buyout price without any warning. Should be a easy case. No hint of merger talk in any previous quarterly calls and the price was awful for most of the shareholders.

1 · Reply

Market Cap	297.40M
Revenue (ttm)	36.33M
Net Income (ttm)	-85.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-234.38%
Debt to Equity Ratio	-2.40

Volume	424,742
Avg Vol	1,097,892
Day's Range	N/A - N/A
Shares Out	53.30M
Stochastic %K	96%
Beta	0.35
Analysts	Sell
Price Target	$11.84